Indonesian Cinnamon (Cinnamomum burmannii)

Indonesian cinnamon (Cinnamomum burmannii) is a Southeast Asian spice whose primary bioactive compound, cinnamaldehyde, drives its antioxidant and anti-inflammatory properties. Its methanolic extracts inhibit nitric oxide production in macrophage cells, while 2-hydroxy-cinnamaldehyde suppresses lipoxygenase-mediated inflammatory pathways.

Origin & History

Indonesian Cinnamon (Cinnamomum burmannii) is a tree species native to Indonesia and Southeast Asia, harvested primarily from its bark for medicinal and culinary use. The active compounds are extracted using ethanol or methanol extraction methods, with essential oils obtained through steam distillation containing 34-92.46% cinnamaldehyde as the primary bioactive compound.

Historical & Cultural Context

C. burmannii has been used in Indonesian traditional medicine for antimicrobial, antioxidant, antidiabetic, anti-inflammatory, and analgesic purposes. Historical use spans traditional systems throughout Indonesia and Southeast Asia, though exact timelines are not specified beyond ongoing folk practices.

Health Benefits

• Antioxidant activity: Methanolic extracts inhibited lipopolysaccharide-induced nitric oxide release in RAW264.7 macrophage cells (in vitro evidence only)
• Anti-inflammatory potential: 2-hydroxy-cinnamaldehyde showed soybean lipoxygenase inhibition with IC50=60 μM (in vitro evidence only)
• Antimicrobial properties: Essential oils rich in cinnamaldehyde and eugenol demonstrate antimicrobial activity (traditional use, no clinical trials)
• Traditional antidiabetic use: Documented in Indonesian folk medicine (no clinical evidence available)
• Analgesic properties: Referenced in traditional medicine systems (no human studies conducted)

How It Works

Cinnamaldehyde and its derivative 2-hydroxy-cinnamaldehyde inhibit soybean lipoxygenase (IC50=60 μM), an enzyme central to arachidonic acid metabolism and leukotriene biosynthesis, reducing pro-inflammatory eicosanoid production. Methanolic extracts suppress lipopolysaccharide (LPS)-induced nitric oxide release in RAW264.7 macrophage cells, likely by downregulating inducible nitric oxide synthase (iNOS) expression. Polyphenolic compounds including procyanidins may also scavenge free radicals via hydrogen atom transfer, contributing to observed antioxidant activity.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specific to Cinnamomum burmannii have been conducted according to available sources. All evidence is limited to in vitro studies using macrophage cell lines and enzyme inhibition assays, with no PMIDs available for human studies.

Clinical Summary

Available evidence for Cinnamomum burmannii is largely limited to in vitro cell-culture studies, with no large-scale randomized controlled trials specific to this species identified in the literature. Laboratory findings show inhibition of nitric oxide in LPS-stimulated RAW264.7 macrophages and lipoxygenase inhibition at IC50=60 μM for 2-hydroxy-cinnamaldehyde, which are mechanistically promising but cannot be directly extrapolated to human dosing or clinical outcomes. Some human research on cinnamon as a genus (particularly Cinnamomum cassia and Cinnamomum verum) suggests modest blood glucose-lowering effects, but species-specific data for C. burmannii remain sparse. Overall, the evidence base is preliminary and insufficient to support firm clinical recommendations.

Nutritional Profile

{"macronutrients": {"carbohydrates": "80.6 g per 100 g", "protein": "4.0 g per 100 g", "fat": "1.2 g per 100 g", "fiber": "53.1 g per 100 g"}, "micronutrients": {"calcium": "1002 mg per 100 g", "iron": "8.32 mg per 100 g", "magnesium": "60 mg per 100 g", "phosphorus": "64 mg per 100 g", "potassium": "431 mg per 100 g", "sodium": "10 mg per 100 g", "zinc": "1.83 mg per 100 g", "vitamin_c": "3.8 mg per 100 g", "vitamin_a": "295 IU per 100 g"}, "bioactive_compounds": {"cinnamaldehyde": "up to 65% of essential oil", "eugenol": "up to 10% of essential oil", "coumarin": "2-5% by weight"}, "bioavailability_notes": "The bioavailability of cinnamaldehyde and eugenol can be influenced by the method of consumption and preparation. Coumarin content should be monitored due to potential hepatotoxicity at high doses."}

Preparation & Dosage

No clinically studied dosage ranges are available for human use. Laboratory studies used ethanolic bark extracts with total phenolic content of 31-89 mg GAE/100g or essential oils standardized to 50-92.46% cinnamaldehyde, but human doses have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ceylon Cinnamon, Turmeric, Ginger, Green Tea Extract, Quercetin

Safety & Interactions

Indonesian cinnamon consumed as a culinary spice is generally recognized as safe, but concentrated extracts or supplements carry a risk of hepatotoxicity due to relatively high coumarin content compared to Ceylon cinnamon (Cinnamomum verum). Individuals taking anticoagulant medications such as warfarin should exercise caution, as cinnamaldehyde may have mild platelet-inhibiting and anticoagulant-potentiating effects. People with diabetes on insulin or oral hypoglycemic agents should monitor blood glucose closely, as additive glucose-lowering effects are plausible. Safety during pregnancy and lactation has not been established for supplemental doses; culinary amounts are generally considered acceptable.